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Cardiovascular disease is a common co-morbidity and leading cause of death in
patients with type 2 diabetes mellitus (T2DM). Glucagon-like peptide 1 (GLP-1) is a
peptide hormone produced by intestinal L cells in response to feeding. Native GLP-1
(7-36) amide is rapidly degraded by diaminopeptidyl peptidase-4 (DPP4) to GLP-1
(9-36) amide, making 9-36a the major circulating form. While it is 7-36a, and not its
metabolites, which exerts trophic effects on islet β-cells, recent studies suggest that
both 7-36a and its metabolites have direct cardiovascular effects, including preserving
cardiomyocyte viability, ameliorating cardiac function, and vasodilation. In particular, the
difference in cardiovascular effects between 7-36a and 9-36a is attracting attention.
Growing evidence has strengthened the presumption that their cardiovascular effects are
overlapping, but distinct and complementary to each other; 7-36a exerts cardiovascular
effects in a GLP-1 receptor (GLP-1R) dependent pathway, whereas 9-36a does so in a
GLP-1R independent pathway. GLP-1 therapies have been developed using two main
strategies: DPP4-resistant GLP-1 analogs/GLP-1R agonists and DPP4 inhibitors, which
both aim to prolong the life-time of circulating 7-36a. One prominent concern that should
be addressed is that the cardiovascular benefits of 9-36a are lacking in these strategies.
This review attempts to differentiate the cardiovascular effects between 7-36a and 9-36a
in order to provide new insights into GLP-1 physiology, and facilitate our efforts to develop
a superior GLP-1-therapy strategy for T2DM and cardiovascular diseases.
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INTRODUCTION
Cardiovascular complications are the primary co-morbidity and leading cause of death in patients
with type 2 diabetes mellitus (T2DM; Killilea, 2002; Mazzone et al., 2008). Epidemiological studies
have shown that patients with cardiovascular disease benefit from good glycemic and lipid control
(AM Committee, 2001; Balkau et al., 2004). Besides its indirect cardiac actions through the control
of glucose and lipid metabolism by modulating insulin and glucagon secretion, GLP-1 may exert
direct effects on heart and blood vessels (Ravassa et al., 2012; Ussher and Drucker, 2012).
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GLP-1 is produced in response to meal ingestion in intestinal
L cells, where it is synthesized as part of the proglucagon
polypeptide, and released following tissue specific post-
translational processing (Drucker, 2006; Brubaker, 2010).
The biological functions of GLP-1 include stimulating insulin
secretion in a glucose-concentration-dependent fashion,
suppressing glucagon release, promoting satiety, and increasing
peripheral glucose disposal, all of which render this incretin to be
an attractive therapeutic target for T2DM (Baggio and Drucker,
2007; Brubaker, 2010; Donnelly, 2012).
Native GLP-1, 7-36a, has a short half-life (1–2 min) due to
rapid enzymatic degradation by DPP4 as well as other enzymes
(Hupe-Sodmann et al., 1995). The DPP4-cleaved form of GLP-
1, 9-36a, is the predominant circulating form (Tomas and
Habener, 2010) (Figure 1). Since 9-36a has no significant insulin-
stimulatory effects and weak affinity to the GLP-1 receptor (GLP-
1R), it was previously perceived as an inactive GLP-1 derivative
(Deacon, 2004).
Over the past decade, accumulated data have highlighted
the cardiovascular effects of 7-36a. However, recent studies
demonstrate that 9-36a, once thought to be inactive, has direct
effects on the cardiovascular system (Deacon, 2004). A thorough
analysis of 7-36a and 9-36a cardiovascular effects, including their
commonality, characteristics, and related mechanisms, suggests
obvious clinical relevance.
One major focus of this review is to examine cardiovascular
effects which differ between 7-36a and its metabolites, 9-36a and
28-36a, and to dissect the interplay of GLP-1R in the heart. This
is necessary to better our understanding of GLP-1 biology, and to
facilitate our efforts for the development of novel GLP-1 therapies
for T2DM and its cardiovascular complications.
CARDIOVASCULAR EFFECTS OF GLP-1
7-36A
Numerous studies have shown that GLP-1 exerts cardioprotective
actions. These include preserving cardiomyocyte and endothelial
cell viability in vitro (Oeseburg et al., 2010), reducing infarct
size and ameliorating cardiac function after myocardial
ischemia/reperfusion injury ex vivo (Bose et al., 2005),
and improving left ventricular function following heart
failure in an animal model (Nikolaidis et al., 2004a). In
conscious dogs with pacing-induced dilated cardiomyopathy,
7-36a administration significantly increased both basal and
insulin-stimulated myocardial glucose uptake, and markedly
Abbreviations: T2DM, type 2 diabetes mellitus; GLP-1, Glucagon-like peptide
1; DPP4, diaminopeptidyl peptidase-4; 7-36a, GLP-1 (7-36) amide; 9-36a, GLP-
1 (9-36) amide; 28-36a, GLP-1 (28-36) amide, 32-36a: GLP-1 (32-36) amide;
GLP-1R, GLP-1 receptor; ROS, reactive oxygen species; NO, nitric oxide; NOS,
nitric oxide synthase; eNOS, endothelial nitric oxide synthase; cGMP, cyclic
guanosine monophosphate; cAMP, cyclic adenosine monophosphate; HUVECs,
human umbilical vein endothelial cells; HCAECs, human coronary artery
endothelial cells; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; ERK1/2,
extracellular signal-regulated kinases 1 and 2; NEP, Neutral endopeptidase; GIP,
gastric inhibitory polypeptide; SDF-1, stromal cell-derived factor-1; AMPK, AMP-
activated protein kinase; VSMCs, vascular smooth muscle cells; ox-LDL, oxidized
low-density lipoprotein; LOX-1, lectin-like oxidized low-density lipoprotein
scavenger receptor-1; FMD, flow-mediated vasodilation.
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FIGURE 1 | Structures of native GLP-1 and its metabolites.
improved hemodynamics in the absence of increases in plasma
insulin (Nikolaidis et al., 2004a). Furthermore, evidence showed
that 7-36a infusion improved underlying mitochondrial protein
abnormalities and age related accumulation of reactive oxygen
species (ROS) in cardiomyocytes of old beagles (Chen et al.,
2014).
Consistent with studies in rats which showed that GLP-
1 analogs may protect the heart against ischemia/reperfusion
injury by improving cardiac energetics and function (Bao
et al., 2011), observations from a pilot clinical study suggest
that therapies aimed to increase GLP-1 action may counteract
oxidative stress, protect from cardiac remodeling, and prevent
cardiovascular events in patients with T2DM associated with low
circulating levels of GLP-1 (Ravassa et al., 2015). A randomized
controlled trial of 172 patients with ST-segment elevation
myocardial infarctions also showed a significant reduction in
infarct size following treatment with a GLP-1R agonist exenatide
(Lønborg et al., 2012).
Due to its short half-life, native GLP-1 needs to be
administered using a continuous intravenous infusion to achieve
pharmacological effects. Indeed, studies using a continuous
intravenous infusion of 7-36a showed beneficial hemodynamic
effects in humans with left ventricular systolic dysfunction after
acute myocardial infarction (Nikolaidis et al., 2004b). However,
since GLP-1 possesses glucose-dependent insulinotrophic effects,
it was not clear whether the observed effects were confounded
by alterations in insulin and/or glucose concentrations between
groups.
To evaluate the effects of GLP-1 on endothelial function
independent of insulin and glucose changes, a study on
non-diabetic subjects, subjected to euglycemic somatostatin
pancreatic clamp during the GLP-1 infusion, suggested that
GLP-1 exerts direct beneficial effects on endothelium-dependent
vasodilatation in humans (Basu et al., 2007). This notion is
further supported by observations from a study in overnight-
fasted, healthy youngmen inwhich infusion of 7-36a significantly
increased microvascular recruitment but not glucose uptake in
the skeletal muscle. Remarkably, this effect was also persistently
observed in the presence or absence of co-infusion of octreotide, a
somatostatin mimetic which attenuates the insulinotropic effects
of GLP-1, suggesting that GLP-1-induced vascular effects are
independent of insulin action (Sjøberg et al., 2014). Furthermore,
it has been shown that, under insulin resistant conditions,
insulin action on microvascular recruitment, and glucose
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transport in skeletal muscles is impaired. GLP-1 treatment
improved insulin-mediated microvascular recruitment, muscle
glucose uptake, and reversed early stages of insulin resistance
induced by high-fat diet feeding in rats (Sjøberg et al.,
2015).
Existing evidence regarding GLP-1 effects on cardiac function
is limited. One clinical study has shown that 7-36a infusion
improves the left ventricular ejection fraction and enhances
functional capacity in patients with chronic heart failure
(Sokos et al., 2006). Another single-center clinical study also
demonstrated that 7-36a treatment was associated with a reduced
requirement for pharmacological and mechanical support while
achieving comparable hemodynamic outcomes after coronary
artery bypass grafting (Müssig et al., 2008). Furthermore,
treatment with GLP-1R agonists has consistently demonstrated
a reduction in blood pressure in patients with T2DM (Klonoff
et al., 2008; Buse et al., 2009). Specifically, it has shown that the
long-lasting GLP-1R agonist liraglutide exerted indirect effects on
the cardiovascular system through glucose and lipid metabolic
control, leading to a decrease in visceral body fat and body weight
in obese patients with T2DM (Jendle et al., 2009).
PROTAGONIST ROLE OF BOTH GLP-1
9-36A AND 28-36A IN
CARDIOPROTECTION
Analysis of the ratio of 7-36a vs. 9-36a in T2DM patients
following GLP-1 infusion, with or without concomitant
administration of a DPP4 inhibitor, found no evidence that
circulating levels of 9-36a were correlated with changes in
plasma glucose (Zander et al., 2006). This is in accordance
with the fact that, unlike 7-36a, both 9-36a and 28-36a show
no effect on insulin secretion or glucose clearance in healthy
humans.
The cardioprotective and vasodilatory actions of GLP-1
appear to be mediated through both GLP-1R-dependent
and independent pathways (Ban et al., 2008). However,
GLP-1 metabolites exert insulinomimetic effects, which may
partially account for the cardioprotective effects of GLP-1
(Nikolaidis et al., 2004b, 2005; Ban et al., 2008). This is
exemplified by the observations that 9-36a retained vasodilatory
and cardioprotective effects in hearts isolated from GLP-
1R−/− mice (Ban et al., 2008). Indeed, 9-36a increased
myocardial glucose uptake and improved left ventricular
performance in dogs with dilated cardiomyopathy (Nikolaidis
et al., 2005). In rats, administration of 9-36a after global ischemia
significantly improved left ventricular pressure, although its
effects in reducing infarct size were marginal (Nikolaidis
et al., 2005). In contrast to intact GLP-1, 9-36a directly
prevents the production of superoxides induced by high
glucose or free fatty acids in human arterial endothelial
cells (Ma et al., 2012). Furthermore, 28-36a, another GLP-
1 metabolite, attenuates myocardial ischemic injury and
significantly reduces infarct size in mice (Mundil et al.,
2012).
SPECULATION FOR AN ALTERNATE GLP-1
RECEPTOR
The GLP-1R is a member of the class B1 family of G protein-
coupled receptors (Kirkpatrick et al., 2012), mainly expressed
in the islet β-cells (Drucker, 2006). Tissue distribution
studies of messenger ribonucleic acid encoding GLP-1R
suggested its expression in extrapancreatic cell types, including
cardiomyocytes and endothelial/vascular smooth muscle cells
(Thorens et al., 1993; Bullock et al., 1996). Recent studies
showed that the expression of GLP-1R was localized to atrial
cardiomyocytes but not in ventricular cardiomyocytes (Kim
et al., 2013; Pyke et al., 2014; Richards et al., 2014). The
cardioprotective effects of GLP-1 were once thought to be
mediated by GLP-1R, given its presence in the cardiovascular
system of both human and various animal models (Ravassa
et al., 2012), and observations that the mice with a GLP-1R
genetic deletion displayed a reduced resting heart rate, elevated
left ventricular end-diastolic pressure, increased left ventricular
thickness, and impaired contractile responses to insulin and
epinephrine (Gros et al., 2003). However, since some of the
beneficial cardiovascular effects of 7-36a recently have been
shown to be present in mice lacking GLP-1R (Ban et al.,
2008), these actions are thus attributed to be 9-36a-mediated
through a GLP-1R-independent pathway (Lobb et al., 2012).
This perception is further supported by the observations that
in GLP-1R−/− mice, both native GLP-1 and 9-36a produced
increased coronary flow in isolated hearts and vasodilation of
mesenteric arteries in both wild type and GLP-1R−/− mice
(Ban et al., 2008). This is consistent with the observations
that while the DPP4 resistant GLP-1R agonist exendin-4 is
no longer effective in enhancing left ventricular end-diastolic
pressure and the rate-pressure product in an isolated rat
heart with the simultaneous administration of the GLP-1R
antagonist exendin (9-39), the enhancement of the rate-
pressure product by 9-36a remains significant (Sonne et al.,
2008), suggesting the presence of an unknown GLP-1R which
interacts with 9-36a, but not exendin-4 (Tomas and Habener,
2010).
THE OVERLAPPING, BUT DISTINCT
FUNCTIONS OF 7-36A AND ITS
METABOLITES
The rapid degradation of 7-36a to 9-36a by DPP4 makes it hard
to determine which form causes which cardioprotective effect.
However, by using either GLP-1R or DPP4 knockout mice, some
studies have shown overlapping but distinct functions for 7-36a
and 9-36a (Figure 2).
Efficacy comparison Nikolaidis et al. performed a head-
to-head efficacy comparison through a 48 h continuous
intravenous infusion of 7-36a and 9-36a in conscious dogs
with dilated cardiomyopathy. They found that both peptides
increased cardiac output and myocardial glucose uptake without
a significant increase in plasma insulin, and improved left
ventricular and systemic hemodynamics (Nikolaidis et al., 2005).
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7-36a
GLP-1R-dependent
9-36a
GLP-1R-independent
myocardial glucose uptake ↑
cardiac function↑
vasodilation↑
prosurvival proteins↑
direct effects on cardiovascular system
improve glucose & lipid metabolism 
obesity ↓  insulin resistance ↓
indirect effects on cardiovascular system
DPP4
FIGURE 2 | Cardiovascular effects: 7-36a vs. 9-36a. The bold line means stronger effects adapted from available experiments. Related references: cardiac
function: (Nikolaidis et al., 2004a,b, 2005; Bose et al., 2005; Sokos et al., 2006; Ban et al., 2008; Müssig et al., 2008; Zaruba et al., 2009; Goodwill et al., 2014);
vasodilation: (Nikolaidis et al., 2004a; Basu et al., 2007; Ban et al., 2008; Green et al., 2008; Klonoff et al., 2008; Buse et al., 2009; Gardiner et al., 2010; Goodwill
et al., 2014); myocardial glucose uptake: (Nikolaidis et al., 2004a, 2005; Ban et al., 2008); prosurvival proteins: (Hausenloy and Yellon, 2007; Sonne et al., 2008; Ban
et al., 2010; Chang et al., 2013); improve glucose and lipid metabolism: (Elahi et al., 2008; Klonoff et al., 2008; Jendle et al., 2009); obesity and insulin resistance:
(Nikolaidis et al., 2005; Elahi et al., 2008; Jendle et al., 2009; Tomas et al., 2011b).
Therefore, 9-36a mimics the effects of 7-36a in stimulating
myocardial glucose uptake and improving left ventricular and
systemic hemodynamics. This evidence indicates that 9-36a is
an active peptide with comparable effects to 7-36a (Nikolaidis
et al., 2005). More evidence substantiates the view that 9-36a
is the predominant mediator in conveying GLP-1 action in the
cardiovascular system (Ban et al., 2008; Green et al., 2008; Ding
et al., 2012). In one study, mass spectrometry was used to analyze
coronary eﬄuents of isolated mouse hearts infused with 7-36a
or 9-36a. After 30 min of a continuous 7-36a infusion, the vast
majority of peptides collected were 9-36a, with only minimal
amounts of 7-36a being detected (Ban et al., 2010).
MODE OF ACTION COMPARISON
Studies by Ban et al. showed that while the vasodilatory effects
of 7-36a occurred in both wild-type and GLP-1R−/− mice, these
effects were abolished by the administration of DPP4 inhibitor
sitagliptin and nitric oxide synthase (NOS) blocker L-NNA. They
also showed that pretreatment with GLP-1 invoked as much
protection from ischemic injury in GLP-1R−/− hearts as in wild
type hearts, providing direct genetic evidence for the existence
of a GLP-1R–independent pathway coupled to cardioprotection
(Ban et al., 2008).
RANGE OF EFFECT
Positive Inotropy and Limiting Ischemic
Injury
An increase in left ventricular diastolic pressure was observed
during pretreatment with 7-36a in wild-type but not GLP-1R−/−
hearts, whereas pretreatment with 9-36a had no such effect. This
suggests that 7-36a, but not 9-36a, has a direct inotropic action
via GLP-1R (Wallner et al., 2015). These findings were further
supported by observations of reduced myocardial infarction size
and improved survival of DPP4 knockout mice (Sauve et al.,
2010). A study by Goodwill et al. was conducted in lean, open
chest and anesthetized swine which received systemic infusions
of saline or GLP-1 (7-36a or 9-36a), followed with coronary
ligation to induce regional ischemia, showing that unlike 9-
36a, treatment with 7-36a significantly improved cardiac output
during regional myocardial ischemia by increasing ventricular
preload without changes in cardiac inotropy (Goodwill et al.,
2014).
In another study by Ban et al. effects of 7-36a and 9-
36a on isolated mouse hearts undergoing ischemia-reperfusion
injury were studied (Ban et al., 2008). They demonstrated that
pretreatment with 7-36a but not 9-36a, and post-treatment with
9-36a resulted in significant functional recovery (indexed by left
ventricular developed pressure) from the ischemia-reperfusion
injury in both wild-type and GLP-1R−/− hearts compared with
untreated controls.
Collectively, these findings suggest that the cardiovascular
effects of 7-36a include inotropic action, glucose uptake,
and ischemic preconditioning dependent on GLP-1R. In
contrast, 9-36a affects post-ischemic recovery of cardiac function
independently of GLP-1R.
Vasodilation
It is important to note that unlike 7-36a or 9-36a, exendin-
4 did not produce vasodilatation or cyclic guanosine
monophosphate (cGMP) release in mesenteric arteries from
both wild-type and GLP-1R−/− mice that were partially
preconstricted with phenylephrine, and the vasodilatory
responses from both 7-36a and 9-36a in arteries were completely
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abolished by pretreatment with the NOS blocker L-NNA
(Ban et al., 2008); it is suggested that the vascular effects of
GLP-1 are mediated via 9-36a and a GLP-1R–independent
mechanism acting partially through NOS-dependent cGMP
formation.
To determine whether the conversion of 7-36a to 9-36a
is required for the vasodilatory action of GLP-1, Ban et al.
conducted a study using DPP4 inhibitor sitagliptin in both wild-
type and GLP-1R−/− mice. Remarkably, DPP4 inhibition to
prevent generation of 9-36a attenuated, but did not abolish,
the beneficial effects of 7-36a on vasodilation, suggesting
that both native GLP-1 (7-36a) and its metabolite 9-36a
possess vasodilatory action. Since both 7-36a and 9-36a
persistently induced vasodilation in arteries from GLP-1R−/−
mice (Ban et al., 2008), these data strongly support the
existence of a vasodilatory signaling mechanism for 7-36a
and 9-36a that is independent of the known functional
GLP-1R.
The effects of 9-36a on endothelial nitric oxide synthase
(eNOS) have been examined in human umbilical vein endothelial
cells (HUVECs). The results revealed that 9-36a increased NO
release, eNOS activity and expression in HUVECs, suggesting
that the vasodilatory effect of NO is a potential mechanism
underlying the protective effects of 9-36a on the cardiovascular
system (Ding and Zhang, 2012). A recent study showed
that the administration of 7-36a in both physiological and
supraphysiological concentrations to a femoral artery infusion
increased microvascular recruitment, but not glucose uptake
in human and rat skeletal muscle (Sjøberg et al., 2014),
suggesting that the vascular effects of GLP-1 are independent
of insulin action. Additionally, GLP-1 induced vasodilation
of isolated pre-constricted mesenteric arteries ex vivo in a
NOS-dependent manner in the absence of insulin (Ban et al.,
2008).
Meta-analysis of clinical trials showed that blood pressure
reduction is frequently observed with chronic administration
of GLP-1R agonists in patients with T2DM (Wang et al.,
2013; Sun et al., 2015). However, administration of DPP-4
inhibitors showed modest reduction or even no changes in
blood pressure in patients with T2DM and in apolipoprotein
E-deficient (ApoE−/−) mice which were susceptible to
atherosclerosis (Matsubara et al., 2012; Zhang and Zhao,
2016). These findings highlight the significance of the GLP-1
metabolite 9-36a in mediating the cardioprotective and
vasodilatory actions of GLP-1 itself. Nevertheless, clinical
studies specifically designed to evaluate the potential
cardiovascular benefits of 9-36a in patients with T2DM are
warranted.
Cytoprotection Against Oxidative Stress
Picatoste et al. reported that native GLP-1 and 9-36a induced
anti-apoptotic/necrotic, anti-hypertrophic, and anti-fibrotic
actions on high fat and/or high glucose-stimulated cardiac
cells in vitro. They observed that while cardiac fibroblasts
did not express GLP-1R, both native GLP-1 and 9-36a
reduced pro-fibrotic expression after stimulation with
high concentrations of palmitate or glucose (Picatoste
et al., 2013). The anti-fibrotic effect of GLP-1 is reversed
by sitagliptin pretreatment, suggesting that 9-36a plays a
direct role. In addition, 9-36a was observed to exert anti-
oxidant effects on cardiac and vascular cells (Picatoste et al.,
2013).
Mitigation of Inflammation, Atherosclerosis
and Stent Restenosis
Liraglutide, a GLP-1R agonist, was observed to reduce tumor
necrosis factor alpha induced nuclear factor KB activation
and lower production of inflammatory genes in HUVECs
and murine endothelial cell line SVEC4, partly via AMP-
activated protein kinase (AMPK) activation (Hattori et al.,
2010). Another GLP-1 receptor agonist, exendin-4, was reported
to reduce the accumulation of monocytes/macrophages in the
arterial wall of ApoE−/− mice partly through activation of the
cAMP/PKA pathway, which may contribute to attenuation of
atherosclerosis (Arakawa et al., 2010). Without affecting glucose
metabolism, exendin-4 consistently reduced the proliferation
of smooth muscle cells and attenuated neointimal formation
after vascular injury in normal C57BL/6 mice, which may
potentially be suitable for the prevention of atherosclerosis
and post stent restenosis (Goto et al., 2011; Hirata et al.,
2013).
Sitagliptin, a DPP4 inhibitor, reduced plaque inflammation
and increased plaque stability, potentially through inhibition
of monocyte migration and macrophage metalloproteinase-9
release in ApoE−/− mice (Vittone et al., 2012). However, in
the PROLOGUE study, no evidence was provided during
the 24-month follow-up period that sitagliptin in addition
to conventional therapy could slow the progression of
carotid intima-media thickening, a surrogate marker for
evaluating atherosclerotic cardiovascular disease, in patients
with T2DM compared with conventional therapy alone
(Oyama et al., 2016). The cause of this discrepancy between
basic experiments and clinical trials remains unknown.
Since, according to the UKPDS and VADT studies efficacy
against cardiovascular events may be demonstrated over
several years or even longer, it cannot be excluded that the
24 month follow-up period in the PROLOGUE study may
be too short to evaluate the anti-atherosclerotic effects of
sitagliptin.
To determine whether the effects of GLP-1 on atherosclerosis
are mediated through a GLP-1R dependent pathway or
not, 7-36a, 9-36a, and 28-36a were overexpressed for 12
weeks in ApoE−/− mice on a high-fat diet using an adeno-
associated viral vector system. Compared to LacZ (control),
all three GLP-1 constructs reduced plaque macrophage
infiltration as well as plaque metalloproteinase-9 expression,
and stabilized plaque by increasing plaque collagen content
and fibrous cap thickness in the aorta (Burgmaier et al.,
2013). The fact that liraglutide, exendin-4, sitagliptin, and
native GLP-1, as well as its metabolites, had comparable anti-
atherosclerotic effects, implying that this cardiovascular benefit
is mediated through both GLP-1R-dependent and independent
pathways.
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ENIGMA OF GLP-1 RECEPTOR IN
CARDIOVASCULAR SYSTEM
GLP-1 Signaling in Cardiomyocytes
The signaling mechanism underlying GLP-1 actions in the islet
β-cells has been extensively studied. Activation of the β-cell GLP-
1R, a G-protein coupled receptor, stimulates the cyclic adenosine
monophosphate (cAMP) dependent signaling that leads to
insulin secretion, and phosphoinositide 3-kinase (PI3K)/protein
kinase B (Akt) signaling pathways which promote β-cell growth
and survival (Wang and Brubaker, 2002; Wang et al., 2004). To
investigate the relevant molecular mechanisms underlying GLP-
1R–dependent cardioprotection, Drucker and colleagues assessed
GLP-1 induced cytoprotective pathways in normal and diabetic
mice with experimental myocardial infarction (Noyan-Ashraf
et al., 2009). They found that the pretreatment of GLP-1R agonist
liraglutide significantly increased the survival rate due to reduced
cardiac rupture and infarct size and improved cardiac output.
This was associated with increased expression and activity of
cardioprotective genes in the mouse heart, including prosurvival
kinase Akt and GSK3β, the nuclear receptor PPARβ/δ, and
the redox-sensitive basic leucine zipper transcription factor
Nrf2, and concomitantly, decreased expression of pro-apoptotic
gene caspase-3 in a GLP-1R antagonist exendin (9-39) sensitive
fashion. These findings suggest that GLP-1 activates pro-
survival signaling pathways in the normal and diabetic mouse
heart, leading to improved cardiac outcomes and enhanced
survival after myocardial infarction in mice (Noyan-Ashraf et al.,
2009). It is known that activation of apoptosis contributes
to cardiomyocyte dysfunction. Using in vitro culture system
in murine HL-1 cardiomyocytes, Ravassa et al. evaluated
cardiac cytoprotective signaling of native GLP-1. They found
that GLP-1 treatment protected the cardiomyocytes from
apoptosis induced by the protein kinase inhibitor staurosporine
and saturated fatty acid palmitate, in which the protective
effects were attenuated by PI3K and/or ERK1/2 inhibition,
suggesting a role for PI3K and ERK1/2 in mediating GLP-
1 cytoprotective effects in the cardiomyocytes (Ravassa et al.,
2011).
Notably, effects of GLP-1 on myocyte electrophysiology were
examined. Studies using whole-cell patch clamp on isolated
canine left ventricular myocytes showed that extracellular
perfusion of 7-36a increased cardiac voltage-gated L-type Ca2+
current, which was blocked by pre-treatment of GLP-1R
antagonist exendin (9-39), or intracellular dialysis with a protein
kinase A inhibitor. It is presumed that, via a GLP-1R and
cAMP dependent signaling pathway, GLP-1 increases these Ca2+
channels activities, leading to Ca2+ influx and increases in the
contractility of cardiac myocytes (Xiao et al., 2011).
To address whether 9-36a induced cardioprotective actions
are coupled to classical GLP-1R, Husain and colleagues
compared cardiac protective effects induced by 9-37a and
GLP-1R agonist exendin-4 in the wild-type and GLP-1R−/−
mice in the presence or absence of exendin (9-39). They
demonstrated that after ischemia-reperfusion (I/R) injury of
isolated mouse hearts, both 9-36a and exendin-4 improved
functional recovery and reduced infarct size. In cultured neonatal
mouse cardiomyocytes, both peptides increased levels of cAMP
and phosphorylation of ERK1/2 and PI3K/Akt activation.
Furthermore, both peptides improved mouse cardiomyocyte
viability and reduced lactate dehydrogenase release and caspase-
3 activation (Ban et al., 2010). These data provide evidence
that both 9-36a and exendin-4 exert cytoprotective effects
through PI3K/Akt and ERK1/2 dependent signaling pathways.
Furthermore, unlike exendin-4, the cardioprotective effects
of 9-36a were preserved in GLP-1R−/− cardiomyocytes,
suggesting that 9-36a induced cardioprotective effects via
an exendin (9-39)-sensitive but distinct from the classical
GLP-1R.
GLP-1 Signaling in Endothelial Cells
Studies by Hattori et al. showed that the administration
of liraglutide to HUVECs dose-dependently enhanced eNOS
phosphorylation, increased NO production, and suppressed NF-
kB activation (Hattori et al., 2010). However, these effects are
attenuated by the AMPK inhibitor compound C or AMPK
small interfering RNA, suggesting that these favorable actions of
liraglutide aremediated at least in part throughAMPK activation.
This observation is corroborated by further evidence showing
that exendin-4, 7-36a, and 9-36a all stimulates proliferation of
human coronary artery endothelial cells (HCAECs) through
eNOS and Akt activation (Erdogdu et al., 2010), implying
that involvement of both GLP-1R-dependent and independent
pathways.
Interestingly, in a single-blind random crossover study,
subjects underwent intravenous infusion of human recombinant
GLP-1 for 105 min and had their endothelial function and
insulin sensitivity measured with ultrasonography through flow-
mediated vasodilation (FMD) and hyperinsulinemic isoglycemic
clamp technique, respectively; 7-36a increased the FMD response
and relatively (16%), albeit not significantly, affected insulin
sensitivity in T2DM subjects, without any effects on FMD and
insulin sensitivity in healthy subjects (Nyström et al., 2004). This
seems inconsistent with previous studies, which demonstrated an
improvement in insulin sensitivity with a 6 week course of 7-36a
in patients with T2DM (Zander et al., 2002), however, it cannot
be excluded that during this very short time (105 min) GLP-1
may not affect insulin sensitivity, and the beneficial endothelial
effects of GLP-1 in patients with T2DM were not fully dependent
on improvements in insulin sensitivity.
To evaluate the effects of exendin-4 and 7-36a on
lipoapoptosis and underlying mechanisms, incubation with
exendin-4 and 7-36a protected HCAECs against lipoapoptosis;
this effect was attenuated by PKA, PI3K/Akt, eNOS, and p38
MAPK, as well as JNK inhibitors and GLP-1R antagonists; the
fact that 9-36a failed to reduce apoptosis in HCAECs also favors
the view that this anti-lipoapoptotic effect is mediated through a
GLP-1R dependent pathway (Erdogdu et al., 2013).
GLP-1 Signaling in Vascular Smooth
Muscle Cells
GLP-1R has been identified in the vascular smooth muscle
cells (VSMCs) of both rodents and humans (Pyke et al.,
2014; Richards et al., 2014). VSMCs play an important
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role in the initiation and progression of atherosclerosis
(Doran et al., 2008). It has shown that treatment with the
critical atherogenesis factor oxidized low-density lipoprotein
(ox-LDL), downregulated GLP-1R expression, and was also
subsequently attenuated by lectin-like oxidized low-density
lipoprotein scavenger receptor-1 (LOX-1) antibody in human
VSMCs. Conversely, over-expression of LOX-1 decreased the
inhibitory effect of liraglutide on the mitochondrial ROS
production in human VSMCs (Dai et al., 2013). Collectively,
these results indicate that Liraglutide reduced ox-LDL-induced
mitochondrial ROS generation in human aortic smooth muscle
cells, furthermore demonstrating that LOX-1 may play a
connective role between GLP-1 activation and ROS interaction
(Dai et al., 2013).
Consistent with previous studies on smooth muscle cells
and wire-mediated endovascular injury in C57BL/6 mice
administered with exendin-4 over 4 weeks (Hirata et al., 2013),
in SD rats subjected to balloon injury of carotid artery, 4 weeks
of exendin-4 treatment selectively reduced smooth muscle
cell proliferation and increased smooth muscle cell apoptosis
(Eriksson et al., 2015). This proapoptotic effect in smooth muscle
cell seems to be mediated through a GLP-1R dependent pathway,
which can be prevented by the GLP-1R antagonist exendin
(9-39).
GLP-1 CLEAVAGE BY NEP
Neutral endopeptidase (NEP) 24.11 is an endopeptidase
expressed in endothelial cells and VSMCs (Graf et al., 1995;
Hupe-Sodmann et al., 1995). It cleaves GLP-1 at several sites
into various metabolites including 28-36a and 32-36a (Hupe-
Sodmann et al., 1995; Plamboeck et al., 2005) (Figure 1).
NEP inhibition, which enhances cGMP, has been proposed
to modulate the progression of heart failure (Birner et al.,
2012) and the prevention of atherogenesis (Ichiki et al.,
2013). A number of studies suggested that the downstream
metabolites of 7-36a and 9-36a under cleavage by NEP 24.11
may account for insulinomimetic effects of 7-36 independently
from GLP-1R (Tomas et al., 2011a; Sharma et al., 2013).
Beneficial cardiac effects have been traced to 28-36a, while
32-36a seems to confer an increase in fatty acid oxidation
and helps to control weight gain (Tomas et al., 2011a,
2015).
9-36A IS EFFECTIVE IN
INSULIN-RESISTANT-ASSOCIATED
CARDIOVASCULAR DISEASES
A study by Gardiner et al. evaluated the regional hemodynamic
effects of 7-36a and 9-36a under physiological conditions
through a persistent infusion of the two peptides in conscious
and chronically instrumented rats (Gardiner et al., 2010).
They found that 7-36a exerted obvious regional hemodynamic
effects including tachycardia, a rise in blood pressure, renal
and mesenteric vasoconstriction, and vasodilation in the
hindquarters. 9-36a, however, was devoid of any cardiovascular
actions in this study (Gardiner et al., 2010). This finding
seemingly contrasts with previous studies showing that 9-
36a improves left ventricular performance and systemic
hemodynamics in conscious dogs with dilated cardiomyopathy
and myocardial insulin resistance (Nikolaidis et al., 2005). It is
possible that, in vivo, the cardiovascular actions of 9-36a only
become apparent under certain pathophysiological conditions,
such as insulin-resistant states. This explanation is also supported
by another study which demonstrated that 9-36a suppresses
hepatic glucose production when infused into obese and insulin
resistant human subjects, but not in healthy human subjects
(Elahi et al., 2008). Furthermore, 9-36a treatment attenuated the
insulin resistance and obesity induced by a high-fat diet feeding
in mice (Tomas et al., 2011b). Since cardiometabolic responses
to native GLP-1 were impaired in obesity and T2DM (Moberly
et al., 2013), these studies support that 9-36a may be particularly
suitable for treating cardiovascular diseases co-morbid with
insulin-resistant-associated diseases such as obesity, T2DM and
metabolic syndrome (Ban et al., 2008; Sonne et al., 2008).
DPP4 INHIBITORS MAY IMPEDE GLP-1
INSULINOMIMETIC EFFECTS
DPP4 Cleavage of Substrates other than
GLP-1, and its Potential Outcome
DPP4 inhibition may also prolong the action of other peptide
hormones cleaved by the protease including gastric inhibitory
polypeptide (GIP), substance P, B-type natriuretic peptide,
and pituitary adenylate cyclase-activating peptide (Mentlein,
2004; Brandt et al., 2006; Sauve et al., 2010). It has been
postulated that the stabilization of these peptide hormones,
neuropeptides, and chemokines may enhance inflammatory or
allergic reactions (Mest and Mentlein, 2005), increase the risk
of tumors (Masur et al., 2006; Kajiyama et al., 2010), and
may harm the antithrombogenic nature of the endothelium
(Krijnen et al., 2012). Moreover, despite limited data on its
cardiovascular relevance, GIP receptors have been recognized
in the atrial and ventricular tissue of rodents, and activation
of these receptors has been linked to lipogenesity (Usdin et al.,
1993; Hansotia et al., 2007; Kim et al., 2007). Whether or
not the increase in GIP due to DPP4 inhibition in humans
is responsible for some of cardiovascular effects of DPP4
inhibitors, and if this is clinically relevant, has yet to be
determined.
Preclinical Studies, Cardioprotection as a
Result of DPP4 Inhibition
A recent study is suggestive of cardiac fibrosis and impairment
of cardiac function following treatment with a DPP4 inhibitor
in diabetic mice (Mulvihill et al., 2016). However, the majority
of preclinical studies allude to cardioprotection as a result of
DPP4 inhibition. It was shown that the treatment with DPP4
inhibitor sitagliptin improved cardiovascular outcomes after
myocardial infarction in non-diabetic mice; similar results were
also obtained in non-diabetic DPP4−/− mice (Sauve et al.,
2010). As stromal cell-derived factor-1 (SDF-1) is an endogenous
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DPP4 substrate which can mobilize endothelial progenitor cells
to sites of vascular or myocardial injury, it is intriguing that
DPP4 inhibition enhances SDF-1, improves cardiac function and
survival after acute myocardial infarction in mice, and increases
circulating endothelial progenitor cells in patients with T2DM
(Zaruba et al., 2009; Fadini et al., 2010).
Clinical Studies, DPP4 Inhibitors vs. GLP-1
Analogs/GLP-1R Agonists
There are two major classes of GLP-1 based therapies that
have been clinically used. One class is the DPP4 inhibitors,
such as sitagliptin, vildagliptin and saxagliptin. The other class
is the GLP-1 analogues or GLP-1R agonists (e.g., liraglutide
and exenatide). There are some important differences between
the two classes. There are a number of potential detrimental
effects associated with the DPP4 inhibition, along with the
inferior clinical efficacy of DPP4 inhibitors in reducing HbA1c
and obesity compared with GLP-1 analogs/GLP-1R agonists
(Association, 2016). Furthermore, the changes in circulating
levels of “active GLP-1” are markedly different between
the two approaches, with DPP4 inhibitors generally raising
concentrations of endogenous 7-36a by 2- to 4-fold whilst
pharmaceutical circulating levels of GLP-1R agonists can be 10-
fold greater than endogenous levels (Pabreja et al., 2014). The
LEADER study, a large double-blind, randomized controlled
trial, has demonstrated that the rate of the first occurrence
of death from cardiovascular causes, non-fatal myocardial
infarction, or non-fatal stroke among patients with T2DM is
lower with liraglutide than with a placebo (Marso et al., 2016a).
In the SUSTAIN-6 study, semaglutide, another GLP-1 analog,
was associated with a significantly lower risk of the primary
composite outcome of death from cardiovascular causes, non-
fatal myocardial infarctions, or non-fatal strokes than did those
receiving a placebo (Marso et al., 2016b). However, the SAVOR-
TIMI 53 trial (saxagliptin) (Scirica et al., 2013), EXAMINE trial
(alogliptin) (White et al., 2013), and TECOS trial (sitagliptin)
(Green et al., 2015) all failed to improve cardiovascular outcomes
with DPP4 inhibition compared to the placebo therapy. The
rate of hospitalization for heart failure was found to be
increased with saxagliptin (Scirica et al., 2013). The greater
beneficial cardiovascular effects and superior clinical efficacy in
the glycemic control and improving obesity achieved by therapies
using GLP-1 analogs/GLP-1R agonists than those by DPP4
inhibition, presumably due to relatively and pharmacologically
higher efficacy in the activation of the GLP-1R in these subjects
on GLP-1 analogs/GLP-1R agonist therapies. Nevertheless, direct
evidence is required to address whether or not the shortage of
9-36a caused by DPP4 inhibitors may be responsible for these
differences.
CURRENT GLP-1 TREATMENT
STRATEGIES AND THEIR INADEQUACY
Numerous studies showed that DPP4 cleavage initiates
degradation pathways that lead to the inactivation and
disposal of GLP-1 (Deacon, 2004; Plamboeck et al., 2005),
current GLP-1 therapies, either under clinical investigation
or approved, were thus developed with a goal of avoiding
GLP-1 degradation by DPP4 (Drucker, 2006). The two
main strategies of GLP-1 therapy—the use of a DPP4-
resistant GLP-1 analogs/GLP-1R agonists, and the use of
DPP4 inhibitors—have been developed and clinically used
for treating diabetes with the aim of prolonging the half-life
of 7-36a.
Recent findings suggest that the cardioprotective effects
of DPP4 inhibitors and DPP4-resistant GLP-1 analogs/GLP-
1R agonists are limited compared to those of GLP-1 in
its native form. In cultured neonatal mouse cardiomyocytes
exposed to either hypoxia reoxygenation or H2O2, both 9-
36a and exendin-4 can improve cardiomyocyte viability and
reduce lactate dehydrogenase release and caspase-3 activation,
by increasing levels of cAMP and prosurvival proteins including
phosphorylated ERK1/2 and Akt (Ban et al., 2010; Chang et al.,
2013). The beneficial effects of both peptides were diminished
when co-incubated with the GLP-1R antagonist Exendin (9-
39). However, the cAMP stimulation and prosurvival effects
of 9-36a, but not exendin-4, remained evident in GLP-1R−/−
cardiomyocytes, suggesting the interaction of 9-36a with a
presumably alternative receptor (Ban et al., 2010). In addition,
9-36a, but not exendin-4, improved the survival of human
aortic endothelial cells after exposure to hypoxia reoxygenation,
or H2O2, through a NOS-dependent mechanism (Ban et al.,
2010). Ex vivo studies using rat conduit arteries established a
vasorelaxation response for both 7-36a and 9-36a, while exendin-
4 produced no vasodilatory activity (Nathanson et al., 2009).
Notably, strategies utilizing DPP4-resistant GLP-1 analogs or
GLP-1R agonists and DPP4 inhibition could not fully invoke the
cardiovascular effects of native GLP-1.
INCREASED ENDOGENOUS GLP-1
PRODUCTION AND CARDIOVASCULAR
BENEFITS
Bariatric surgery is an effective treatment for patients with
severe obesity. It results in sustained weight loss, remarkable
improvement of T2DM, and significant reduction of
cardiovascular events (Sjöström et al., 2012; Cotugno et al.,
2015). Notably, in a retrospective study conducted in patients
with T2DM and severe obesity, bariatric surgery was more
effective in reducing cardiovascular risk profiles than standard
hypoglycemic therapy in conjunction with liraglutide (Cotugno
et al., 2015). Native GLP-1 secretion in response to meals is
dramatically increased after bariatric surgery, particularly after
Roux-en-Y gastric bypasses and sleeve gastrectomies. Although
reduced fasting DPP4 activity has been observed after the
Roux-en-Y gastric bypass surgery, the precise mechanisms have
not yet been fully elucidated. It has shown that postoperative
improvement of glucose tolerance as well as insulin secretion
is reduced by the GLP-1 receptor antagonist, exendin (9-39)
(Karra et al., 2010; Alam et al., 2011; Manning et al., 2015). This
evidence suggests that increased endogenous GLP-1 production
is responsible, in part, for these beneficial effects.
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An alternative strategy for enhancing endogenous GLP-1
secretion may be to increase the growth and viability of L cells.
Recent studies suggested that lipotoxicity occurring in the GLP-
1 secreting L cells could represent a mechanism underlying
impaired GLP-1 secretion in response tomeal ingestion in T2DM
patients. Indeed, in vitro studies showed that treatment of L cells
with metformin, insulin, or exendin-4 could protect against L
cell lipoapotosis, and stimulate GLP-1 secretion from the L cells
(Kappe et al., 2012, 2013a,b; Kuhre et al., 2016). In an in vivo
study in mice received 12-weeks control or high-fat diet, a 55%
but no significant (p = 0.134) reduction of the number of GLP-
1-positive cells was indicated in the high-fat diet group, and this
effect was indicated to be reversed by 14 days administration of
metformin; however, no significant effect can be determined of
a high-fat diet or metformin treatment on fasting or prandial
serum GLP-1 (7-36a and 9-36a) levels (Kappe et al., 2014).
Therefore, further studies are necessary to confirm the treatment
effect of metformin on L cells in vivo.
Increasing evidence demonstrates that both 7-36a and 9-36a
exert cardiovascular effects. It is conceivable that a therapeutic
strategy to prolong native GLP-1 action (Wang et al., 2010)
may have superior beneficial cardiovascular effects along with
glycemic and metabolic control.
CONCLUSIONS
Recent advances in GLP-1 biology and incretin-based therapies
suggest that the mechanism of action for native GLP-1 appears
to be a varied spectrum characterized by insulinotropic and
insulinomimetic features. Compelling evidence suggests that
7-36a and 9-36a have direct cardiovascular effects which are
overlapping in some ways, but are distinct and complementary
in others. While 7-36a exerts cardiovascular effects in a GLP-
1R-dependent fashion, mainly improving myocardial glucose
uptake, 9-36a acts through GLP-1R-independent processes,
largely accounting for vasodilation, amelioration of endothelial
dysfunction, increased cardiac function, and cytoprotection
against ischemic-reperfusion injury. As such, it may be
particularly relevant with regards to insulin-resistance-associated
cardiovascular diseases (Nikolaidis et al., 2005; Ban et al., 2008;
Erdogdu et al., 2010). Furthermore, both 7-36a and 9-36a exert
indirect effects on the cardiovascular system, such as improving
metabolic control to make the prognosis of cardiovascular
diseases more optimistic. Additionally, the cleavage of native
GLP-1 (7-36) by alternative pathways such as NEP 24.11 into
metabolites may account for some of the cardiovascular benefits
of native GLP-1 either directly or indirectly, by correcting
metabolic syndrome (Tomas et al., 2011c, 2015).
Therefore, the two current GLP-1-therapy strategies, DPP4-
resistant GLP-1 analogs/GLP-1R agonists and DPP4 inhibitors,
may not have an optimistic outlook due to the lack of
9-36a and its associated cardioprotective virtues, as well as
previously mentioned detrimental effects. The development of
new strategies in GLP-1-therapy to simultaneously prolong the
actions of native GLP-1 and its metabolites may achieve profound
therapeutic effects in the context of glycemic control and cardiac
protection.
AUTHOR CONTRIBUTIONS
QW contributed to the conception and design of the study;
JL and JZ contributed to the literature search; JL, JZ, and
QW contributed to the data analysis; JL, JZ, SW, HL, AF, and
QW contributed to the discussion; JL and QW contributed to
drafting the article; SW, HL, and AF contributed to the editorial
reading; HL and AF contributed to the reference accuracy; QW
is responsible for the integrity of the work as a whole. All authors
have revised the manuscript critically for important intellectual
content and given final approval of the version to be published.
FUNDING
This work was supported by grants from the Canadian Diabetes
Association (CDA, OG-3-13-4066-QW), Juvenile Diabetes
Research Foundation (JDRF, 2015-64-Q-R), and National
Science Foundation China (NSFC, 81570518, 81370877).
REFERENCES
Alam, M. L., Van der Schueren, B. J., Ahren, B., Wang, G. C., Swerdlow, N.
J., Arias, S., et al. (2011). Gastric bypass surgery, but not caloric restriction,
decreases dipeptidyl peptidase-4 activity in obese patients with type 2
diabetes. Diabetes Obes. Metab. 13, 378–381. doi: 10.1111/j.1463-1326.2011.
01358.x
AM Committee (2001). Study rationale and design of ADVANCE:
action in diabetes and vascular disease–preterax and diamicron MR
controlled evaluation. Diabetologia 44, 1118–1120. doi: 10.1007/s0012501
00612
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., et al.
(2010). Inhibition of monocyte adhesion to endothelial cells and attenuation of
atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Diabetes 59, 1030–1037. doi: 10.2337/db09-1694
Association, A. D. (2016). 7. Approaches to glycemic treatment. Diabetes Care 39,
S52–S59. doi: 10.2337/dc16-S010
Baggio, L. L., and Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP.
Gastroenterology 132, 2131–2157. doi: 10.1053/j.gastro.2007.03.054
Balkau, B., Hu, G., Qiao, Q., Tuomilehto, J., Borch-Johnsen, K., Pyorala, K.,
et al. (2004). Prediction of the risk of cardiovascular mortality using a score
that includes glucose as a risk factor. The DECODE Study. Diabetologia 47,
2118–2128. doi: 10.1007/s00125-004-1574-5
Ban, K., Kim, K. H., Cho, C. K., Sauve, M., Diamandis, E. P., Backx,
P. H., et al. (2010). Glucagon-like peptide (GLP)-1(9-36)amide-mediated
cytoprotection is blocked by exendin(9-39) yet does not require the
known GLP-1 receptor. Endocrinology 151, 1520–1531. doi: 10.1210/en.
200-1197
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S. S., Drucker, D. J., and
Husain, M. (2008). Cardioprotective and vasodilatory actions of glucagon-
like peptide 1 receptor are mediated through both glucagon-like peptide 1
receptor-dependent and -independent pathways. Circulation 117, 2340–2350.
doi: 10.1161/CIRCULATIONAHA.107.739938
Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T., Szapacs, M., Citerone,
D. R., et al. (2011). Albiglutide, a long lasting glucagon-like peptide-
1 analog, protects the rat heart against ischemia/reperfusion injury:
evidence for improving cardiac metabolic efficiency. PLoS ONE 6:e23570.
doi: 10.1371/journal.pone.0023570
Frontiers in Physiology | www.frontiersin.org 9 January 2017 | Volume 8 | Article 15
Li et al. Cardiovascular Effects: 7-36a vs. 9-36a
Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., and Joyner,
M. J. (2007). Beneficial effects of GLP-1 on endothelial function in
humans: dampening by glyburide but not by glimepiride. Am. J.
Physiol. Endocrinol. Metab. 293, E1289–E1295. doi: 10.1152/ajpendo.
00373.2007
Birner, C., Ulucan, C., Bratfisch, M., Götz, T., Dietl, A., Schweda, F., et al. (2012).
Antihypertrophic effects of combined inhibition of the renin-angiotensin
system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-
induced experimental heart failure. Naunyn Schmiedebergs Arch. Pharmacol.
385, 1117–1125. doi: 10.1007/s00210-012-0791-6
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., and Yellon,
D. M. (2005). Glucagon-like peptide 1 can directly protect the
heart against ischemia/reperfusion injury. Diabetes 54, 146–151.
doi: 10.2337/diabetes.54.1.146
Brandt, I., Lambeir, A. M., Ketelslegers, J. M., Vanderheyden, M., Scharpé,
S., and De Meester, I. (2006). Dipeptidyl-peptidase IV converts intact B-
type natriuretic peptide into its des-SerPro form. Clin. Chem. 52, 82–87.
doi: 10.1373/clinchem.2005.057638
Brubaker, P. L. (2010). Minireview: update on incretin biology: focus on glucagon-
like peptide-1. Endocrinology 151, 1984–1989. doi: 10.1210/en.2010-0115
Bullock, B. P., Heller, R. S., and Habener, J. F. (1996). Tissue distribution of
messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.
Endocrinology 137, 2968–2978.
Burgmaier, M., Liberman, A., Möllmann, J., Kahles, F., Reith, S., Lebherz,
C., et al. (2013). Glucagon-like peptide-1 (GLP-1) and its split products
GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe(-
)/(-) mice. Atherosclerosis 231, 427–435. doi: 10.1016/j.atherosclerosis.2013.0
8.033
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., et al.
(2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a
26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Lancet 374, 39–47. doi: 10.1016/S0140-6736(09)60659-0
Chang, G., Zhang, D., Yu, H., Zhang, P., Wang, Y., Zheng, A., et al. (2013).
Cardioprotective effects of exenatide against oxidative stress-induced injury.
Int. J. Mol. Med. 32, 1011–1020. doi: 10.3892/ijmm.2013.1475
Chen, M., Angeli, F. S., Shen, Y. T., and Shannon, R. P. (2014). GLP-
1 (7-36) amide restores myocardial insulin sensitivity and prevents the
progression of heart failure in senescent beagles. Cardiovasc. Diabetol. 13:115.
doi: 10.1186/s12933-014-0115-x
Cotugno, M., Nosso, G., Saldalamacchia, G., Vitagliano, G., Griffo, E., Lupoli, R.,
et al. (2015). Clinical efficacy of bariatric surgery versus liraglutide in patients
with type 2 diabetes and severe obesity: a 12-month retrospective evaluation.
Acta Diabetol. 52, 331–336. doi: 10.1007/s00592-014-0644-5
Dai, Y., Mercanti, F., Dai, D., Wang, X., Ding, Z., Pothineni, N. V., et al. (2013).
LOX-1, a bridge betweenGLP-1R andmitochondrial ROS generation in human
vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 437, 62–66.
doi: 10.1016/j.bbrc.2013.06.035
Deacon, C. F. (2004). Circulation and degradation of GIP and GLP-1. Horm.
Metab. Res. 36, 761–765. doi: 10.1055/s-2004-826160
Ding, L., and Zhang, J. (2012). Glucagon-like peptide-1 activates endothelial nitric
oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin.
33, 75–81. doi: 10.1038/aps.2011.149
Ding, L., Zhang, J., Zhang, S. W., and Zhao, W. Z. (2012). [Effects of
glucagon-like peptide 1(9-36) on endothelial nitric oxide synthase in human
umbilical vein endothelial cells]. Zhonghua Yi Xue Za Zhi 92, 3008–3011.
doi: 10.3760/cma.j.issn.0376-2491.2012.42.016
Donnelly, D. (2012). The structure and function of the glucagon-like
peptide-1 receptor and its ligands. Br. J. Pharmacol. 166, 27–41.
doi: 10.1111/j.1476-5381.2011.01687.x
Doran, A. C., Meller, N., andMcNamara, C. A. (2008). Role of smooth muscle cells
in the initiation and early progression of atherosclerosis. Arterioscler. Thromb.
Vasc. Biol. 28, 812–819. doi: 10.1161/ATVBAHA.107.159327
Drucker, D. J. (2006). The biology of incretin hormones. Cell Metab. 3, 153–165.
doi: 10.1016/j.cmet.2006.01.004
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener,
J. F., et al. (2008). GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36)
amide, is a glucoregulatory peptide. Obesity (Silver Spring) 16, 1501–1509.
doi: 10.1038/oby.2008.229
Erdogdu, O., Eriksson, L., Xu, H., Sjoholm, A., Zhang, Q., and Nyström, T.
(2013). Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K,
eNOS, p38 MAPK, and JNK pathways. J. Mol. Endocrinol. 50, 229–241.
doi: 10.1530/JME-12-0166
Erdogdu, O., Nathanson, D., Sjöholm, A., Nyström, T., and Zhang, Q. (2010).
Exendin-4 stimulates proliferation of human coronary artery endothelial
cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires
GLP-1 receptor. Mol. Cell. Endocrinol. 325, 26–35. doi: 10.1016/j.mce.2010.
04.022
Eriksson, L., Saxelin, R., Röhl, S., Roy, J., Caidahl, K., Nyström, T., et al.
(2015). Glucagon-Like Peptide-1 receptor activation does not affect re-
endothelialization but reduces intimal hyperplasia via direct effects on smooth
muscle cells in a nondiabetic model of arterial injury. J. Vasc. Res. 52, 41–52.
doi: 10.1159/000381097
Fadini, G. P., Boscaro, E., Albiero, M., Menegazzo, L., Frison, V., de Kreutzenberg,
S., et al. (2010). The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases
circulating endothelial progenitor cells in patients with type 2 diabetes:
possible role of stromal-derived factor-1alpha. Diabetes Care 33, 1607–1609.
doi: 10.2337/dc10-0187
Gardiner, S. M., March, J. E., Kemp, P. A., Bennett, T., and Baker, D. J.
(2010). Possible involvement of GLP-1(9-36) in the regional haemodynamic
effects of GLP-1(7-36) in conscious rats. Br. J. Pharmacol. 161, 92–102.
doi: 10.1111/j.1476-5381.2010.00867.x
Goodwill, A. G., Tune, J. D., Noblet, J. N., Conteh, A. M., Sassoon, D., Casalini,
E. D., et al. (2014). Glucagon-like peptide-1 (7-36) but not (9-36) augments
cardiac output during myocardial ischemia via a Frank-Starling mechanism.
Basic Res. Cardiol. 109:426. doi: 10.1007/s00395-014-0426-9
Goto, H., Nomiyama, T., Mita, T., Yasunari, E., Azuma, K., Komiya, K., Arakawa,
M., et al. (2011). Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces
intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 405,
79–84. doi: 10.1016/j.bbrc.2010.12.131
Graf, K., Koehne, P., Gräfe, M., Zhang,M., Auch-Schwelk,W., and Fleck, E. (1995).
Regulation and differential expression of neutral endopeptidase 24.11 in human
endothelial cells. Hypertension 26, 230–235. doi: 10.1161/01.HYP.26.2.230
Green, B. D., Hand, K. V., Dougan, J. E., McDonnell, B. M., Cassidy, R. S., and
Grieve, D. J. (2008). GLP-1 and related peptides cause concentration-dependent
relaxation of rat aorta through a pathway involving KATP and cAMP. Arch.
Biochem. Biophys. 478, 136–142. doi: 10.1016/j.abb.2008.08.001
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., et al.
(2015). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N.
Engl. J. Med. 373, 232–242. doi: 10.1056/NEJMoa1501352
Gros, R., You, X., Baggio, L. L., Kabir, M. G., Sadi, A. M., Mungrue, I. N., et al.
(2003). Cardiac function in mice lacking the glucagon-like peptide-1 receptor.
Endocrinology 144, 2242–2252. doi: 10.1210/en.2003-0007
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., et al.
(2007). Extrapancreatic incretin receptors modulate glucose homeostasis,
body weight, and energy expenditure. J. Clin. Invest. 117, 143–152.
doi: 10.1172/JCI25483
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., et al.
(2010). A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates
nitric oxide production and exerts anti-inflammatory action in endothelial
cells. Diabetologia 53, 2256–2263. doi: 10.1007/s00125-010-1831-8
Hausenloy, D. J., and Yellon, D. M. (2007). Reperfusion injury salvage kinase
signalling: taking a RISK for cardioprotection. Heart Fail. Rev. 12, 217–234.
doi: 10.1007/s10741-007-9026-1
Hirata, Y., Kurobe, H., Nishio, C., Tanaka, K., Fukuda, D., Uematsu, E., et al.
(2013). Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates
neointimal hyperplasia after vascular injury. Eur. J. Pharmacol. 699, 106–111.
doi: 10.1016/j.ejphar.2012.11.057
Hupe-Sodmann, K., McGregor, G. P., Bridenbaugh, R., Göke, R., Göke, B.,
Thole, H., et al. (1995). Characterisation of the processing by human neutral
endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate
specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 58,
149–156. doi: 10.1016/0167-0115(95)00063-H
Ichiki, T., Izumi, R., Cataliotti, A., Larsen, A. M., Sandberg, S. M., and Burnett, J.
C. Jr. (2013). Endothelial permeability in vitro and in vivo: protective actions
of ANP and omapatrilat in experimental atherosclerosis. Peptides 48, 21–26.
doi: 10.1016/j.peptides.2013.07.020
Frontiers in Physiology | www.frontiersin.org 10 January 2017 | Volume 8 | Article 15
Li et al. Cardiovascular Effects: 7-36a vs. 9-36a
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M.,
et al. (2009). Weight loss with liraglutide, a once-daily human glucagon-like
peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to
metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes.
Metab. 11, 1163–1172. doi: 10.1111/j.1463-1326.2009.01158.x
Kajiyama, H., Shibata, K., Ino, K., Mizutani, S., Nawa, A., and Kikkawa,
F. (2010). The expression of dipeptidyl peptidase IV (DPPIV/CD26) is
associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian
carcinoma cells. Cancer Sci. 101, 347–354. doi: 10.1111/j.1349-7006.2009.
01378.x
Kappe, C., Holst, J. J., Zhang, Q., and Sjöholm, A. (2012). Molecular mechanisms
of lipoapoptosis and metformin protection in GLP-1 secreting cells. Biochem.
Biophys. Res. Commun. 427, 91–95. doi: 10.1016/j.bbrc.2012.09.010
Kappe, C., Patrone, C., Holst, J. J., Zhang, Q., and Sjöholm, A. (2013b). Metformin
protects against lipoapoptosis and enhances GLP-1 secretion from GLP-
1-producing cells. J. Gastroenterol. 48, 322–332. doi: 10.1007/s00535-012-
0637-5
Kappe, C., Zhang, Q., Holst, J. J., Nyström, T., and Sjöholm, A. (2013a). Evidence
for paracrine/autocrine regulation of GLP-1-producing cells. Am. J. Physiol.
Cell Physiol. 305, C1041–C1049. doi: 10.1152/ajpcell.00227.2013
Kappe, C., Zhang, Q., Nyström, T., and Sjöholm, Å. (2014). Effects of high-
fat diet and the anti-diabetic drug metformin on circulating GLP-1 and
the relative number of intestinal L-cells. Diabetol. Metab. Syndr. 6:70.
doi: 10.1186/1758-5996-6-70
Karra, E., Yousseif, A., and Batterham, R. L. (2010). Mechanisms facilitating
weight loss and resolution of type 2 diabetes following bariatric surgery. Trends
Endocrinol. Metab. 21, 337–344. doi: 10.1016/j.tem.2010.01.006
Killilea, T. (2002). Long-term consequences of type 2 diabetes mellitus: economic
impact on society and managed care. Am. J. Manag. Care 8, S441–S449.
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S.,
et al. (2013). GLP-1 receptor activation and Epac2 link atrial natriuretic
peptide secretion to control of blood pressure. Nat. Med. 19, 567–575.
doi: 10.1038/nm.3128
Kim, S. J., Nian, C., and McIntosh, C. H. (2007). Resistin is a key mediator of
glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein
lipase (LPL) activity in adipocytes. J. Biol. Chem. 282, 34139–34147.
doi: 10.1074/jbc.M704896200
Kirkpatrick, A., Heo, J., Abrol, R., and Goddard, W. A. III. (2012). Predicted
structure of agonist-bound glucagon-like peptide 1 receptor, a class B G
protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 109, 19988–19993.
doi: 10.1073/pnas.1218051109
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe,
J. H., et al. (2008). Exenatide effects on diabetes, obesity, cardiovascular risk
factors and hepatic biomarkers in patients with type 2 diabetes treated for at
least 3 years. Curr. Med. Res. Opin. 24, 275–286. doi: 10.1185/030079908X2
53870
Krijnen, P. A., Hahn, N. E., Kholová, I., Baylan, U., Sipkens, J. A., van Alphen, F.
P., et al. (2012). Loss of DPP4 activity is related to a prothrombogenic status of
endothelial cells: implications for the coronary microvasculature of myocardial
infarction patients. Basic Res. Cardiol. 107:233. doi: 10.1007/s00395-011-0
233-5
Kuhre, R. E., Holst, J. J., and Kappe, C. (2016). The regulation of function,
growth and survival of GLP-1-producing L-cells. Clin. Sci. 130, 79–91.
doi: 10.1042/CS20150154
Lobb, I., Mok, A., Lan, Z., Liu, W., Garcia, B., and Sener, A. (2012). Supplemental
hydrogen sulphide protects transplant kidney function and prolongs recipient
survival after prolonged cold ischaemia-reperfusion injury by mitigating
renal graft apoptosis and inflammation. BJU Int. 110, E1187–E1195.
doi: 10.1111/j.1464-410X.2012.11526.x
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen,
A. B., et al. (2012). Exenatide reduces reperfusion injury in patients with
ST-segment elevation myocardial infarction. Eur. Heart J. 33, 1491–1499.
doi: 10.1093/eurheartj/ehr309
Ma, T., Du, X., Pick, J. E., Sui, G., Brownlee, M., and Klann, E. (2012). Glucagon-
like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity
and memory deficits in Alzheimer’s disease model mice. J. Neurosci. 32,
13701–13708. doi: 10.1523/JNEUROSCI.2107-12.2012
Manning, S., Pucci, A., and Batterham, R. L. (2015). GLP-1: a mediator of the
beneficial metabolic effects of bariatric surgery? Physiology (Bethesda) 30,
50–62. doi: 10.1152/physiol.00027.2014
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A.,
et al. (2016a). Semaglutide and cardiovascular outcomes in patients with type 2
diabetes. N. Engl. J. Med. 375, 1834–1844. doi: 10.1056/NEJMoa1607141
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E.,
Nauck, M. A., et al. (2016b). Liraglutide and cardiovascular outcomes in type 2
diabetes. N. Engl. J. Med. 375, 311–322. doi: 10.1056/NEJMoa1603827
Masur, K., Schwartz, F., Entschladen, F., Niggemann, B., and Zaenker,
K. S. (2006). DPPIV inhibitors extend GLP-2 mediated tumour
promoting effects on intestinal cancer cells. Regul. Pept. 137, 147–155.
doi: 10.1016/j.regpep.2006.07.003
Matsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama,
E., et al. (2012). A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin,
improves endothelial function and reduces atherosclerotic lesion formation
in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol. 59, 265–276.
doi: 10.1016/j.jacc.2011.07.053
Mazzone, T., Chait, A., and Plutzky, J. (2008). Cardiovascular disease risk in type
2 diabetes mellitus: insights from mechanistic studies. Lancet 371, 1800–1809.
doi: 10.1016/S0140-6736(08)60768-0
Mentlein, R. (2004). Cell-surface peptidases. Int. Rev. Cytol. 235, 165–213.
doi: 10.1016/S0074-7696(04)35004-7
Mest, H. J., and Mentlein, R. (2005). Dipeptidyl peptidase inhibitors as new
drugs for the treatment of type 2 diabetes. Diabetologia 48, 616–620.
doi: 10.1007/s00125-005-1707-5
Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G.,
Casalini, E. D., et al. (2013). Impaired cardiometabolic responses to glucagon-
like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res. Cardiol. 108:365.
doi: 10.1007/s00395-013-0365-x
Mulvihill, E. E., Varin, E. M., Ussher, J. R., Campbell, J. E., Bang, K. W., Abdullah,
T., et al. (2016). Inhibition of dipeptidyl peptidase-4 impairs ventricular
function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes
65, 742–754. doi: 10.2337/db15-1224
Mundil, D., Beca, S., Cameron-Vendrig, A., El-Mounayri, O., Momen, A., Backx,
P. H., et al. (2012). GLP-1 [28-36] Exerts Direct Cardioprotective Effects,
Activating Pro-Survival Kinases and Soluble Adenylyl Cyclase. Circulation 126,
A13657–A13657. doi: 10.1186/1475-2840-13-12
Müssig, K., Oncü, A., Lindauer, P., Heininger, A., Aebert, H., Unertl, K., et al.
(2008). Effects of intravenous glucagon-like peptide-1 on glucose control and
hemodynamics after coronary artery bypass surgery in patients with type 2
diabetes. Am. J. Cardiol. 102, 646–647. doi: 10.1016/j.amjcard.2008.06.029
Nathanson, D., Erdogdu, O., Pernow, J., Zhang, Q., and Nystrom, T.
(2009). Endothelial dysfunction induced by triglycerides is not restored
by exenatide in rat conduit arteries ex vivo. Regul. Pept. 157, 8–13.
doi: 10.1016/j.regpep.2009.07.003
Nikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias,
L., et al. (2004a). Recombinant glucagon-like peptide-1 increases myocardial
glucose uptake and improves left ventricular performance in conscious
dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955–961.
doi: 10.1161/01.CIR.0000139339.85840.DD
Nikolaidis, L. A., Elahi, D., Shen, Y. T., and Shannon, R. P. (2005).
Active metabolite of GLP-1 mediates myocardial glucose uptake and
improves left ventricular performance in conscious dogs with dilated
cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, H2401–H2408.
doi: 10.1152/ajpheart.00347.2005
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi,
D., et al. (2004b). Effects of glucagon-like peptide-1 in patients with
acute myocardial infarction and left ventricular dysfunction after successful
reperfusion. Circulation 109, 962–965. doi: 10.1161/01.CIR.0000120505.913
48.58
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A. M., Zhou, Y. Q., Riazi, A.
M., et al. (2009). GLP-1R agonist liraglutide activates cytoprotective pathways
and improves outcomes after experimental myocardial infarction in mice.
Diabetes 58, 975–983. doi: 10.2337/db08-1193
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., et al.
(2004). Effects of glucagon-like peptide-1 on endothelial function in type 2
Frontiers in Physiology | www.frontiersin.org 11 January 2017 | Volume 8 | Article 15
Li et al. Cardiovascular Effects: 7-36a vs. 9-36a
diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol.
Metab. 287, E1209–E1215. doi: 10.1152/ajpendo.00237.2004
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst,
W. H., and Sillje, H. H. (2010). Glucagon-like peptide 1 prevents reactive
oxygen species-induced endothelial cell senescence through the activation
of protein kinase A. Arterioscler. Thromb. Vasc. Biol. 30, 1407–1414.
doi: 10.1161/ATVBAHA.110.206425
Oyama, J., Murohara, T., Kitakaze, M., Ishizu, T., Sato, Y., Kitagawa, K., et al.
(2016). The effect of sitagliptin on carotid artery atherosclerosis in type 2
diabetes: the PROLOGUE randomized controlled trial. PLoSMed. 13:e1002051.
doi: 10.1371/journal.pmed.1002051
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D., and Furness, S. G. (2014).
Molecular mechanisms underlying physiological and receptor pleiotropic
effects mediated by GLP-1R activation. Br. J. Pharmacol. 171, 1114–1128.
doi: 10.1111/bph.12313
Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Ares-Carrasco, S.,
Egido, J., et al. (2013). Sitagliptin reduces cardiac apoptosis, hypertrophy
and fibrosis primarily by insulin-dependent mechanisms in experimental
type-II diabetes. Potential roles of GLP-1 isoforms. PLoS ONE 8:e78330.
doi: 10.1371/journal.pone.0078330
Plamboeck, A., Holst, J. J., Carr, R. D., and Deacon, C. F. (2005). Neutral
endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the
degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia
48, 1882–1890. doi: 10.1007/s00125-005-1847-7
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup,
P., et al. (2014). GLP-1 receptor localization in monkey and human tissue:
novel distribution revealed with extensively validated monoclonal antibody.
Endocrinology 155, 1280–1290. doi: 10.1210/en.2013-1934
Ravassa, S., Beaumont, J., Huerta, A., Barba, J., Coma-Canella, I., González,
A., et al. (2015). Association of low GLP-1 with oxidative stress is related
to cardiac disease and outcome in patients with type 2 diabetes mellitus: a
pilot study. Free Radic. Biol. Med. 81, 1–12. doi: 10.1016/j.freeradbiomed.2015.
01.002
Ravassa, S., Zudaire, A., and Díez, J. (2012). GLP-1 and cardioprotection: from
bench to bedside. Cardiovasc. Res. 94, 316–323. doi: 10.1093/cvr/cvs123
Ravassa, S., Zudaire, A., Carr, R. D., and Díez, J. (2011). Antiapoptotic effects of
GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 300,
H1361–H1372. doi: 10.1152/ajpheart.00885.2010
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C.,
Trapp, S., et al. (2014). Identification and characterization of GLP-1 receptor-
expressing cells using a new transgenic mouse model. Diabetes 63, 1224–1233.
doi: 10.2337/db13-1440
Sauve, M., Ban, K., Momen, M. A., Zhou, Y. Q., Henkelman, R. M., Husain,
M., et al. (2010). Genetic deletion or pharmacological inhibition of dipeptidyl
peptidase-4 improves cardiovascular outcomes after myocardial infarction in
mice. Diabetes 59, 1063–1073. doi: 10.2337/db09-0955
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J.,
Hirshberg, B., et al. (2013). Saxagliptin and cardiovascular outcomes in
patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326.
doi: 10.1056/NEJMoa1307684
Sharma, R., McDonald, T. S., Eng, H., Limberakis, C., Stevens, B. D., Patel, S., et al.
(2013). In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived
metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human
hepatocytes. Drug Metab. Dispos. 41, 2148–2157. doi: 10.1124/dmd.113.054254
Sjøberg, K. A., Holst, J. J., Rattigan, S., Richter, E. A., and Kiens, B. (2014).
GLP-1 increases microvascular recruitment but not glucose uptake in human
and rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 306, E355–E362.
doi: 10.1152/ajpendo.00283.2013
Sjøberg, K. A., Rattigan, S., Jeppesen, J. F., Lundsgaard, A.M., Holst, J. J., and Kiens,
B. (2015). Differential effects of glucagon-like peptide-1 on microvascular
recruitment and glucose metabolism in short- and long-term insulin resistance.
J. Physiol. (Lond). 593, 2185–2198. doi: 10.1113/JP270129
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H.,
et al. (2012). Bariatric surgery and long-term cardiovascular events. JAMA 307,
56–65. doi: 10.1001/jama.2011.1914
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., and Shannon, R. P. (2006).
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction
and functional status in patients with chronic heart failure. J. Card. Fail. 12,
694–699. doi: 10.1016/j.cardfail.2006.08.211
Sonne, D. P., Engstrøm, T., and Treiman, M. (2008). Protective effects of GLP-
1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion
injury in rat heart. Regul. Pept. 146, 243–249. doi: 10.1016/j.regpep.2007.10.001
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., et al. (2015). Impact of
GLP-1 receptor agonists on blood pressure, heart rate and hypertension
among patients with type 2 diabetes: a systematic review and network meta-
analysis. Diabetes Res. Clin. Pract. 110, 26–37. doi: 10.1016/j.diabres.2015.
07.015
Thorens, B., Porret, A., Bühler, L., Deng, S. P., Morel, P., and Widmann, C.
(1993). Cloning and functional expression of the human islet GLP-1 receptor.
Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist
of the receptor. Diabetes 42, 1678–1682. doi: 10.2337/diab.42.11.1678
Tomas, E., and Habener, J. F. (2010). Insulin-like actions of glucagon-like
peptide-1: a dual receptor hypothesis. Trends Endocrinol. Metab. 21, 59–67.
doi: 10.1016/j.tem.2009.11.007
Tomas, E., Stanojevic, V., and Habener, J. F. (2011a). GLP-1-derived nonapeptide
GLP-1(28-36)amide targets to mitochondria and suppresses glucose
production and oxidative stress in isolated mouse hepatocytes. Regul.
Pept. 167, 177–184. doi: 10.1016/j.regpep.2011.01.003
Tomas, E., Stanojevic, V., McManus, K., Khatri, A., Everill, P., Bachovchin, W.
W., et al. (2015). GLP-1(32-36)amide pentapeptide increases basal energy
expenditure and inhibits weight gain in obese mice. Diabetes 64, 2409–2419.
doi: 10.2337/db14-1708
Tomas, E., Wood, J. A., Stanojevic, V., and Habener, J. F. (2011b). Glucagon-like
peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes
and hepatic steatosis in diet-induced obese mice. Diabetes Obes. Metab. 13,
26–33. doi: 10.1111/j.1463-1326.2010.01316.x
Tomas, E., Wood, J. A., Stanojevic, V., and Habener, J. F. (2011c). GLP-1-derived
nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes
and hepatic steatosis in diet-induced obese mice. Regul. Pept. 169, 43–48.
doi: 10.1111/j.1463-1326.2010.01316.x doi: 10.1016/j.regpep.2011.04.006
Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., and Bonner, T. I. (1993).
Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive
intestinal peptide receptor family, is widely distributed in peripheral organs and
the brain. Endocrinology 133, 2861–2870.
Ussher, J. R., and Drucker, D. J. (2012). Cardiovascular biology of the incretin
system. Endocr. Rev. 33, 187–215. doi: 10.1210/er.2011-1052
Vittone, F., Liberman, A., Vasic, D., Ostertag, R., Esser, M., Walcher, D.,
et al. (2012). Sitagliptin reduces plaque macrophage content and stabilises
arteriosclerotic lesions in Apoe (−/−) mice. Diabetologia 55, 2267–2275.
doi: 10.1007/s00125-012-2582-5
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M.,Wakula, P., Ljubojevic, S., et al.
(2015). Exenatide exerts a PKA-dependent positive inotropic effect in human
atrial myocardium: GLP-1R mediated effects in human myocardium. J. Mol.
Cell. Cardiol. 89, 365–375. doi: 10.1016/j.yjmcc.2015.09.018
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., et al. (2013).
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and
liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15, 737–749.
doi: 10.1111/dom.12085
Wang, Q., and Brubaker, P. L. (2002). Glucagon-like peptide-1 treatment delays
the onset of diabetes in 8 week-old db/db mice. Diabetologia 45, 1263–1273.
doi: 10.1007/s00125-002-0828-3
Wang, Q., Chen, K., Liu, R., Zhao, F., Gupta, S., Zhang, N., et al. (2010). Novel
GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS ONE
5:e12734. doi: 10.1371/journal.pone.0012734
Wang, Q., Li, L., Xu, E., Wong, V., Rhodes, C., and Brubaker, P. L. (2004).
Glucagon-like peptide-1 regulates proliferation and apoptosis via activation
of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47, 478–487.
doi: 10.1007/s00125-004-1327-5
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M.,
Bakris, G. L., et al. (2013). Alogliptin after acute coronary syndrome in patients
with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335. doi: 10.1056/NEJMoa
1305889
Xiao, Y. F., Nikolskaya, A., Jaye, D. A., and Sigg, D. C. (2011). Glucagon-
like peptide-1 enhances cardiac L-type Ca2+ currents via activation of
Frontiers in Physiology | www.frontiersin.org 12 January 2017 | Volume 8 | Article 15
Li et al. Cardiovascular Effects: 7-36a vs. 9-36a
the cAMP-dependent protein kinase A pathway. Cardiovasc. Diabetol. 10:6.
doi: 10.1186/1475-2840-10-6
Zander, M., Madsbad, S., Deacon, C. F., and Holst, J. J. (2006). The metabolite
generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1
has no influence on plasma glucose levels in patients with type 2 diabetes.
Diabetologia 49, 369–374. doi: 10.1007/s00125-005-0098-y
Zander, M., Madsbad, S., Madsen, J. L., and Holst, J. J. (2002). Effect of 6-week
course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity,
and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359,
824–830. doi: 10.1016/S0140-6736(02)07952-7
Zaruba, M. M., Theiss, H. D., Vallaster, M., Mehl, U., Brunner, S., David, R.,
et al. (2009). Synergy between CD26/DPP-IV inhibition and G-CSF improves
cardiac function after acute myocardial infarction. Cell Stem Cell 4, 313–323.
doi: 10.1016/j.stem.2009.02.013
Zhang, X., and Zhao, Q. (2016). Effects of dipeptidyl peptidase-4 inhibitors on
blood pressure in patients with type 2 diabetes: A systematic review and
meta-analysis. J. Hypertens. 34, 167–175. doi: 10.1097/HJH.0000000000000782
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Li, Zheng, Wang, Lau, Fathi and Wang. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 13 January 2017 | Volume 8 | Article 15
